<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799249</url>
  </required_header>
  <id_info>
    <org_study_id>G1T28-208</org_study_id>
    <secondary_id>2020-004930-39</secondary_id>
    <nct_id>NCT04799249</nct_id>
  </id_info>
  <brief_title>Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)</brief_title>
  <acronym>PRESERVE 2</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G1 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G1 Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating&#xD;
      the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and&#xD;
      carboplatin in patients receiving first- or second-line treatment for locally advanced&#xD;
      unresectable/metastatic TNBC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will have two separate cohorts (Cohort 1 and Cohort 2). Both cohorts will follow&#xD;
      the same general study conduct/design with similar primary and key secondary endpoints and&#xD;
      identical treatment arms.&#xD;
&#xD;
        -  Cohort 1 will evaluate patients receiving first-line therapy, regardless of programmed&#xD;
           death-ligand 1 (PD-L1) status, who are programmed cell death protein 1 (PD-1)/PD-L1&#xD;
           inhibitor therapy naïve.&#xD;
&#xD;
        -  Cohort 2 will evaluate PD-L1 positive patients receiving second-line therapy following&#xD;
           prior PD-1/PD-L1 inhibitor therapy in the locally advanced unresectable/metastatic&#xD;
           setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">October 25, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-Blind Trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on Overall Survival (OS)</measure>
    <time_frame>Cohort 1:From date of randomization up to 39 months</time_frame>
    <description>(Cohort 1):To evaluate the effect of trilaciclib on overall survival (OS) compared with placebo in patients receiving first-line gemcitabine and carboplatin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on Overall Survival (OS)</measure>
    <time_frame>Cohort 2: From date of randomization up to 28 months</time_frame>
    <description>(Cohort 2): To evaluate the effect of trilaciclib on OS compared with placebo in patients receiving gemcitabine and carboplatin as second-line therapy after treatment with a PD-1/PD-L1 inhibitor in the locally advanced unresectable/metastatic setting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life/Effects On Chemotherapy-Induced Fatigue</measure>
    <time_frame>Cycle 1 Day 1 (each cycle is 21 days) up to 14 months</time_frame>
    <description>To assess the effect of trilaciclib on patients' quality of life as measured by time to first confirmed deterioration of fatigue compared with placebo in patients receiving gemcitabine and carboplatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myeloprotective Effects</measure>
    <time_frame>Cycle 1 Day 1 (each cycle is 21 days) up to 14 months</time_frame>
    <description>Occurrence of cytopenias, febrile neutropenia, hospitalization due to chemotherapy-induced myelosuppression, RBC and platelet transfusions, growth factor administration, and dose reductions and delays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From date of randomization up to 14 months)</time_frame>
    <description>To evaluate the effect of trilaciclib on progression-free survival (PFS) compared with placebo in patients receiving gemcitabine and carboplatin.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>TNBC - Triple-Negative Breast Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Trilaciclib + gemcitabine + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trilaciclib (240mg/m2) + gemcitabine (1000 mg/m2) and carboplatin (AUC 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + gemcitabine + carboplatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects in the placebo arm will follow the same schedule as the trilaciclib arm, but will receive placebo instead of trilaciclib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trilaciclib</intervention_name>
    <description>Trilaciclib administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.</description>
    <arm_group_label>Trilaciclib + gemcitabine + carboplatin</arm_group_label>
    <other_name>G1T28</other_name>
    <other_name>COSELA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.</description>
    <arm_group_label>Placebo + gemcitabine + carboplatin</arm_group_label>
    <other_name>0.9% normal saline</other_name>
    <other_name>5 % Dextrose in water (D5W)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle.</description>
    <arm_group_label>Placebo + gemcitabine + carboplatin</arm_group_label>
    <arm_group_label>Trilaciclib + gemcitabine + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin administered IV on Day 1 and Day 8 of each 21-day cycle.</description>
    <arm_group_label>Placebo + gemcitabine + carboplatin</arm_group_label>
    <arm_group_label>Trilaciclib + gemcitabine + carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;/= 18 years of age with evaluable locally advanced unresectable or metastatic&#xD;
             TNBC.&#xD;
&#xD;
          2. Documentation of triple negative breast cancer (estrogen and progesterone receptor &lt;1%&#xD;
             and HER2-negative)&#xD;
&#xD;
          3. Prior systemic therapies (Cohort 1 only):&#xD;
&#xD;
               1. No prior systemic therapy in the locally advanced unresectable/metastatic setting&#xD;
                  including chemotherapy, targeted therapy, immunotherapy, or investigational&#xD;
                  agents.&#xD;
&#xD;
               2. Prior PD-1/PD-L1 inhibitor treatment is not permitted in any setting, including&#xD;
                  in the neoadjuvant setting.&#xD;
&#xD;
               3. Time between completion of last treatment with curative intent and first&#xD;
                  metastatic recurrence must be ≥ 6 months.&#xD;
&#xD;
          4. Prior systemic therapies (Cohort 2 only):&#xD;
&#xD;
               1. Documentation of PD-L1 positive status&#xD;
&#xD;
               2. Treated with a PD-1/PD-L1 inhibitor for a minimum duration of 4 months in the&#xD;
                  locally advanced unresectable/metastatic setting and as the most recent therapy.&#xD;
&#xD;
          5. Radiation therapy for metastatic disease is permitted. There is no required minimum&#xD;
             washout period for radiation therapy. Patients should be recovered from the effects of&#xD;
             radiation.&#xD;
&#xD;
          6. Archival tumor tissue must be available or a fresh biopsy must be obtained, unless&#xD;
             approved by the Medical Monitor.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          8. Adequate organ function as demonstrated by normal laboratory values&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with gemcitabine in any setting.&#xD;
&#xD;
          2. Prior treatment with carboplatin in the locally advanced unresectable/metastatic&#xD;
             setting.&#xD;
&#xD;
             Prior carboplatin in the (neo)adjuvant/curative setting is permitted as long as it was&#xD;
             completed ≥ 6 months prior to the first metastatic recurrence.&#xD;
&#xD;
          3. Presence of central nervous system (CNS) metastases and/or leptomeningeal disease&#xD;
             requiring immediate treatment with radiation therapy or steroids.&#xD;
&#xD;
          4. Receipt of any cytotoxic chemotherapy within 14 days prior to the first dose of study&#xD;
             drugs.&#xD;
&#xD;
          5. QTcF interval &gt;480 msec at Screening (confirmed in triplicate). For patients with&#xD;
             ventricular pacemakers, QTcF &gt;500 msec.&#xD;
&#xD;
          6. Known hypersensitivity to carboplatin or other platinum-containing compounds, or&#xD;
             mannitol&#xD;
&#xD;
          7. Pregnant or lactating women&#xD;
&#xD;
          8. Prior hematopoietic stem cell or bone marrow transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Contact</last_name>
    <role>Study Director</role>
    <affiliation>G1 Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>G1Therapeutics Clinical Contact</last_name>
    <phone>919-213-9835</phone>
    <email>clinicalinfo@g1therapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alabama Oncology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia Preston</last_name>
      <email>lydia.preston@alabamaoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Abercrombie</last_name>
      <email>stephanie.abercrombie@alabamaoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shailendra Lakhanpal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ironwood Cancer and Research Centers</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Swanson</last_name>
      <phone>480-398-7674</phone>
      <email>dana.swanson@ironwoodcrc.com</email>
    </contact>
    <investigator>
      <last_name>Sujith Kalmadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Heitkamp</last_name>
      <phone>805-879-0670</phone>
      <email>hheitkam@ridleytreecc.org</email>
    </contact>
    <investigator>
      <last_name>Ryan Kendle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Cancer Institute at MedStar Washington Hospital Center - Oncology Research</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Gallagher, MD</last_name>
      <phone>202-877-0928</phone>
      <email>christopher.gallagher@medstar.net</email>
    </contact>
    <contact_backup>
      <last_name>MaryAnne Hinkson</last_name>
      <phone>202-877-9386</phone>
      <email>MaryAnne.Hinkson@Medstar.net</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Gallagher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North (SCRI)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dinah Welsh-Barnes</last_name>
      <phone>727-216-1143</phone>
      <phone_ext>13097</phone_ext>
      <email>dibarnes@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Gail Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Snyder</last_name>
      <email>ian.snyder@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Trinh Williams</last_name>
      <email>trinh.williams@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Axia Soyano Muller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Glidden</last_name>
      <phone>847-259-4482</phone>
      <email>andrea.glidden@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Urszula Sobol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Clinton</city>
        <state>Maryland</state>
        <zip>20735</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Almand</last_name>
      <email>missy.almand@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carol Tweed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Specialists</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Watson</last_name>
      <phone>816-932-1880</phone>
      <email>awatson@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Pluard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Genetics of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khin Win</last_name>
      <phone>702-952-2140</phone>
      <email>khin.win@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Anu Thummala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Mauney</last_name>
      <phone>980-442-9434</phone>
      <email>elizabeth.mauney@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Antoinette Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Cook</last_name>
      <phone>917-371-5230</phone>
      <email>heather.cook@compassoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Marilyn Arnesen</last_name>
      <phone>9173715230</phone>
      <email>marilyn.arnesen@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jay Andersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPC Pinnacle Health Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Plassmeyer</last_name>
      <phone>412-648-6417</phone>
      <email>plassmeyerjm@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Heim</last_name>
      <phone>717-724-6765</phone>
      <email>heimb2@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lu Kit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Hematology Oncology</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Banas</last_name>
      <phone>215-706-2034</phone>
      <email>becki.banas1@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Potz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Tucker</last_name>
      <phone>423-622-6212</phone>
      <email>kimberly.tucker@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Brooke Daniel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Cancer - Oncology</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Lammers</last_name>
      <phone>901-379-0703</phone>
      <email>Philip.Lammers@bmg.md</email>
    </contact>
    <investigator>
      <last_name>Philip Lammers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology (SCRI)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Simons</last_name>
      <email>lisa.simons@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Denise Yardley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Austin Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian Heaven</last_name>
      <phone>512-427-9400</phone>
      <email>marian.heaven@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Debra Patt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Jones, RN</last_name>
      <phone>214-265-2080</phone>
      <email>nancy.jones@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Kristi McIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Lopez</last_name>
      <phone>214-370-1000</phone>
      <email>rita.lopez2@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joyce O'Shaughnessy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-West Texas</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca S Garcia</last_name>
      <phone>915-544-6750</phone>
      <email>becky.garcia@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Ines Sanchez-Rivera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Houston Memorial City</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Fru</last_name>
      <phone>713-467-1704</phone>
      <email>nina.fru@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michelina Cairo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerrie Marie Shojaie</last_name>
      <phone>281-894-8822</phone>
      <email>kerrie.shojaie@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Malik Henna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology P.A.</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Maxfield</last_name>
      <phone>903-579-9800</phone>
      <email>shelly.maxfield@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcy Sullivan</last_name>
      <phone>571-222-2200</phone>
      <email>marcy.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Anne Favret, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendi A Gobhardt</last_name>
      <phone>757-466-8683</phone>
      <email>wendi.gobhardt@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Danso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Azer</last_name>
      <phone>+61 7 54706535</phone>
      <email>mary.azer@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Houston</last_name>
      <phone>+61 4 18986403</phone>
      <email>kathleen.houston@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Michelle Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre - Oncology</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>08006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard De Boer</last_name>
      <phone>+61 3 9342 7695</phone>
      <email>Richard.deBoer@petermac.org</email>
    </contact>
    <contact_backup>
      <last_name>Sherene Loi</last_name>
      <phone>+61 3 855959335</phone>
      <email>Sherene.Loi@petermac.org</email>
    </contact_backup>
    <investigator>
      <last_name>Shom Goal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center - Burgas</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blagovesta Geneva</last_name>
      <phone>+359897927765</phone>
      <email>blagovestarumenovageneva@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Krasimir Nikolov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mhat Dr.Tota Venkova</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonka Popova</last_name>
      <phone>+359897927765</phone>
    </contact>
    <investigator>
      <last_name>Bonka Popova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LTD&quot;Brothers&quot;</name>
      <address>
        <city>Batumi</city>
        <state>Ajaria</state>
        <zip>6010'</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teimuraz Gogitidze</last_name>
      <phone>+995568000600</phone>
      <email>mamology@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tamar Kontselidze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acad.Fridon Todua Medical Center- Research Institute of Clinical Medicine</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamar Melkadze</last_name>
      <phone>+995940289</phone>
      <email>tmelkadze@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Tamar Melkadze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine Harmony Health</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gvantsa Zaridze</last_name>
      <phone>+995599201136</phone>
      <email>gvantsa.zaridze@arensia-em.com</email>
    </contact>
    <investigator>
      <last_name>Marina Maglakelidze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LTDIsraeli-Georgian Medical Research Clinic Helsicore</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterine Arkania</last_name>
      <phone>+995 99 922081</phone>
      <email>arkadiaek@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ekaterine Arkania, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consilium Medulla , Multiprofile Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lia Abshilava</last_name>
      <phone>+995322304502</phone>
      <email>abshilavalia@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Lia Abshilava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Personalized Medicine LTD</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre Tavartkiladze, MD</last_name>
      <phone>+995322485800</phone>
      <email>alexandre.tavartkiladze@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alexandre Tavartkiladze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LTD &quot;Institute Of Clinical Oncology&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gia Nemsadze</last_name>
      <phone>+995558186184</phone>
      <email>Gia.Nemsadze@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gia Nemsadze</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IMSP Institutul Oncologic, ARENSIA Exploratory Medicine</name>
      <address>
        <city>Chisinau</city>
        <zip>MD-2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Crijanovschi</last_name>
      <email>adrian.crijanovschi@arensia-em.com</email>
    </contact>
    <investigator>
      <last_name>Iurie Bulat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sawiec</last_name>
      <phone>+48122954135</phone>
      <email>anna.sawiec@pratia.pl</email>
    </contact>
    <investigator>
      <last_name>Aleksandra Grela - Wojewoda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MED-POLONIA Sp.z o.o.</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel Echaust</last_name>
      <phone>+ 48 505758992</phone>
      <email>pawel.echaust@medpolonia.com.pl</email>
    </contact>
    <contact_backup>
      <last_name>Katarzyna Stencel</last_name>
      <phone>48 61 665 42 42</phone>
      <email>k.stencel@post.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Rodryg Ramlau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Poznan</name>
      <address>
        <city>Skorzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justyna Topolewska</last_name>
      <phone>48 506 969 916</phone>
      <email>j.nowik@examen.pl</email>
    </contact>
    <contact_backup>
      <last_name>Marta Filipowska</last_name>
      <phone>48 506 969 916</phone>
      <email>marta.filipowska@pratia.com</email>
    </contact_backup>
    <investigator>
      <last_name>Renata Szoszkiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut MSF Sp. z. o.o.</name>
      <address>
        <city>Łódź</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Grubiak</last_name>
      <email>grubiak.marta@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ewa Kalinka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío Avenida Manuel Siurot s/n</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Bernal Iriarte</last_name>
      <phone>+34-671 533 373</phone>
      <email>lauraonco.huvr@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mª Ángeles Oyarzabal Cespedes</last_name>
      <phone>+34 955 013 068</phone>
      <email>oyarzabalma@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ruiz Borrego Manuel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari General de Catalunya Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Ovalle</last_name>
      <phone>+34 935 46 01 43</phone>
      <email>eovalle@oncorosell.com</email>
    </contact>
    <contact_backup>
      <last_name>Horcas Ruiz</last_name>
      <phone>0034 934651337</phone>
      <email>lhorcas@quironsalud.es</email>
    </contact_backup>
    <investigator>
      <last_name>Xavier González Farré</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine</name>
      <address>
        <city>Kapitanivka</city>
        <state>Kyivska Oblast</state>
        <zip>08112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Varytska</last_name>
      <phone>+380503361132</phone>
      <email>hanna.varytska@arensia-em.com</email>
    </contact>
    <contact_backup>
      <last_name>Kateryna Veremienko</last_name>
      <phone>+380503361132</phone>
      <email>kateryna.veremienko@arensia-em.com</email>
    </contact_backup>
    <investigator>
      <last_name>Valeriy Cheshuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sumskyi obl. klinichnyi onkol.</name>
      <address>
        <city>Sumy</city>
        <state>Sums'ka Oblast</state>
        <zip>40022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Skrypnyk</last_name>
      <phone>+380509264234</phone>
      <email>g_skrypnyk@ukr.net</email>
    </contact>
    <investigator>
      <last_name>Vynnychenko Ihor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Ternopil obl klin onkodyspanser&quot; TOR</name>
      <address>
        <city>Ternopil</city>
        <state>Ternopil's'ka Oblast</state>
        <zip>46023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oleksandr Bolyukh</last_name>
      <phone>+380352268680</phone>
      <email>bolukh1972@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Iryna Havryliuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KP &quot;Volynskyi obl med tsentr onkolohii&quot; VOR</name>
      <address>
        <city>Lutsk</city>
        <state>Volyns'ka Oblast</state>
        <zip>63000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergii Spetruk</last_name>
      <phone>+380954250764</phone>
      <email>serg.onko@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ivan Sinielnikov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>carboplatin</keyword>
  <keyword>solid tumors</keyword>
  <keyword>breast</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>TNBC</keyword>
  <keyword>trilaciclib</keyword>
  <keyword>cyclin-dependent kinase 4/6 inhibitor</keyword>
  <keyword>CDK 4/6 Inhibitor</keyword>
  <keyword>triple-negative breast cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>chemotherapy-induced fatigue</keyword>
  <keyword>HER2-negative</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>immune checkpoint inhibitor therapy</keyword>
  <keyword>chemotherapy-induced myelosuppression</keyword>
  <keyword>myeloprotection</keyword>
  <keyword>myeloprotective</keyword>
  <keyword>PD-1/PD-L1 inhibitor therapy</keyword>
  <keyword>advanced</keyword>
  <keyword>stage 4</keyword>
  <keyword>preserve</keyword>
  <keyword>PRESERVE 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

